Achillion Pharmaceuticals Hits New 1-Year High at $13.80 (ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) hit a new 52-week high during mid-day trading on Thursday , StockRatingsNetwork reports. The stock traded as high as $13.80 and last traded at $13.23, with a volume of 8,454,999 shares changing hands. The stock had previously closed at $13.06.
A number of research firms have recently commented on ACHN. Analysts at Credit Suisse reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, August 21st. They now have a $10.00 price target on the stock, up previously from $4.00. Separately, analysts at Deutsche Bank upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, August 18th. They now have a $17.00 price target on the stock, up previously from $6.00. Finally, analysts at Maxim Group reiterated a “buy” rating on shares of Achillion Pharmaceuticals in a research note on Friday, August 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.50.
The stock has a 50-day moving average of $8.51 and a 200-day moving average of $5.26. The company’s market cap is $1.331 billion.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. Analysts expect that Achillion Pharmaceuticals will post $-0.69 EPS for the current fiscal year.
In other Achillion Pharmaceuticals news, major shareholder Ra Capital Management, Llc unloaded 835,293 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $11.63, for a total value of $9,714,457.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.